Clinical effect of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer.
- Author:
Zheng-gang ZHU
1
;
Rui TANG
;
Min YAN
;
Jun CHEN
;
Qiu-meng YANG
;
Shen LI
;
Xue-xin YAO
;
Jun ZHANG
;
Hao-ran YIN
;
Yan-zhen LIN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; methods; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Peritoneal Neoplasms; drug therapy; secondary; Prognosis; Stomach Neoplasms; drug therapy; mortality; pathology; Survival Rate; Treatment Outcome
- From: Chinese Journal of Gastrointestinal Surgery 2006;9(1):26-30
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical effect of intraoperative peritoneal hyperthermic chemotherapy (IPHC) for advanced gastric cancer (AGC).
METHODSA total of 118 AGC patients with serosal invasion were enrolled in this study from 1998 to 2001. Among these cases, 96 patients without macroscopic peritoneal metastases were selected for prophylactic study, including 42 cases with IPHC and 54 cases without IPHC as control. Other 22 patients with macroscopic peritoneal metastases were selected for therapeutic study, including 10 cases with IPHC and 12 without IPHC. Postoperative survival rate and peritoneal recurrence were compared.
RESULTSFor prophylactic study, the 1, 2 and 4 years survival rates were 85.7%, 81.0% and 63.9% respectively in the patients with IPHC,significantly higher than 77.3%, 61.0% and 50.8% in the patients without IPHC. Cox ratio hazard model revealed that IPHC procedure was an independent prognostic factor. More patients in the control group suffered from peritoneal recurrence than those in IPHC group (34.7% vs 10.3%). For therapeutic study,the median survival period of the patients with IPHC was 10 months, higher than 5 months in the patients without IPHC. The overall 1, 2, 4 year survival rates were 76.9%, 69.2%, 55.2% respectively in all cases with IPHC, higher than 66.2%, 49.7%, 41.4% in the cases without IPHC.
CONCLUSIONIPHC procedure can improve the prognosis of AGC patients with serosal invasion, reduce the risk for peritoneal recurrence, and is an independent prognostic factor.
